Agalsidase beta vs pegunigalsidase alfa

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Fabry Disease

Shared mechanism: Alpha-galactosidase A (GLA / α-Gal A) · full Fabry Disease pipeline

Agalsidase beta · Fabrazyme

Marketed by Sanofi

Approved in Fabry Diseaseenzyme
Weak signal

NCT00837824 · Phase 2 · terminated

This study was randomized but not blinded, had no placebo control, and was terminated early after enrolling only a sixth of its planned patients; with just one clinical event recorded across both dose groups, it could not produce a meaningful comparison of Fabrazyme's effect on disease progression.

Reported efficacy

Skin Globotriaosylceramide (GL-3) Clearance From Superficial Skin Capillary Endothelium (Baseline, Week 52, Week 156 and Week 260): Participants with zero skin GL-3 score: 75% vs 80% at week 52, 56.3% vs 80% at week 156, and 68.8% vs 66.7% at week 260 (0.5 mg/kg every 2 weeks vs 1.0 mg/kg every 4 weeks). (unclear)

Result source: NCT00701415

pegunigalsidase alfa

Marketed by Chiesi Farmaceutici and partners

Approved in Fabry Diseaseenzyme replacement
Weak signal

NCT03566017 · Phase 3 · completed

This was a genuine open-label extension of studies PB-102-F03, PB-102-F20, and PB-102-F30, with 97 participants and 81 completing the extension, but it was single-arm and unblinded with no comparator. Its primary focus was treatment-related adverse events rather than a randomized clinical efficacy comparison, so the findings provide useful long-term safety and descriptive follow-up evidence but cannot establish comparative treatment benefit. Its registered primary outcome on ClinicalTrials.gov is "Number of Participants With Treatment-related Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: October 2027 · NCT05710692 (registry estimate)

Reported efficacy

Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) (met)

Result source: NCT02795676

Results for Fabry Disease

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

pegunigalsidase alfa
Annualized Change (Slope) in Estimated Glomerular Filtration Rate (eGFR) (24 months): PRX-102 (Pegunigalsidase Alfa) -2.514 mL/min/1.73 m^2/year (95% CI -3.788 to -1.24) | Agalsidase Beta -2.155 mL/min/1.73 m^2/year (95% CI -3.805 to -0.505) NCT02795676 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Agalsidase beta

Time to CV Cerebrovascular Progression or Death 1.15 months1mg/kg Every 2 Weeks
time to event · months
No placebo or comparator arm
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2 · converted to months from 35 days as posted
Available safety results

Agalsidase beta

Dropout rate
0%3mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
show 1 more result
0%1mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
Discontinued due to AEs
—3mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
show 1 more result
—1mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
Serious AEs
11.1%3mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
show 1 more result
36.4%1mg/kg Every 2 Weeks
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
Most frequent reported AEs
3mg/kg Every 2 Weeks
oedema peripheral 33.3%
headache 22.2%
muscle spasms 22.2%
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2
show 1 more result
1mg/kg Every 2 Weeks
abdominal pain 18.2%
pyrexia 18.2%
transient ischaemic attack 18.2%
NCT00837824 · Phase 2 · monotherapy · Chronic Kidney Disease, Fabry Disease · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Agalsidase beta's landscape · pegunigalsidase alfa's landscape